Your session is about to expire
← Back to Search
NAD Supplementation for Brain Health in Aging
Study Summary
This trial will test whether Nicotinamide Riboside, a form of Vitamin B3, can improve brain health and memory.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken NAD enhancers like nicotinamide riboside or mononucleotide in the last 4 weeks.You have a serious mental illness, such as severe depression that is not well controlled with medication, or you have a problem with alcohol or drug abuse.I am between 60 and 85 years old.I can see and hear well enough to undergo tests.I understand and can agree to the study's procedures and risks.I have not had a stroke, excluding TIA, in the last 60 days.I do not have active brain disorders like multiple sclerosis, uncontrolled seizures, or active brain cancer.My recent tests show my kidneys are not working well.You have difficulty seeing or hearing that would make it hard for you to complete the study assessments.
- Group 1: NR
- Group 2: Control
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the central aim of this research endeavor?
"Over an 8 week period, this trial will be monitoring participants' neurovascular coupling via transcranial Doppler. Secondary objectives include tracking changes in attention (measured through Flanker Inhibitory Control and Attention Test), executive function (assessed with the Dimensional Change Card Sort Test) and episodic memory (evaluated by Picture Sequence Memory Test). All metrics are rated on a scale of 0-10, where higher scores denote better performance; outcomes will be reported as percent change from baseline pre-treatment values."
What potential risks may be associated with the ingestion of Nicotinamide riboside?
"Nicotinamide riboside has been approved and is consequently rated 3 on the safety scale due to this being a Phase 4 trial."
Is enrollment for this clinical experiment still ongoing?
"Detailed on the clinicaltrials.gov platform, this trial is not taking in any more participants at the moment. This investigation was introduced December 1st 2022 and last revised October 31st of that same year. While no longer enrolling patients, there are currently 246 other studies actively recruiting study subjects."
Is the age restriction for this research study limited to those older than 55 years old?
"This clinical trial has a predetermined age range for entry, with the minimum being 60 and the maximum 85."
What qualifications must potential participants of this clinical trial satisfy?
"214 volunteers, aged between 60 and 85 years old, are sought for this trial. Prospective participants must be able to read English and understand the consent form, have good hearing/vision capabilities, and possess a valid Mini-Mental State Exam score of 24 or higher."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger